A randomized, double blind, placebo controlled, multicenter clinical trial to assess the efficacy and safety of Emblica officinalis extract in patients with dyslipidemia.
- 2019-01-22
- RCT · n = 98
- BMC complementary and alternative medicine 19(1)
- Haridas Upadya
- S Prabhu
- Aravinda Prasad
- Deepa Subramanian
- Swati Gupta
- Ajay Goel
- PubMed: 30670010
- DOI: 10.1186/s12906-019-2430-y
- High evidence
- Clinical
The ratio of Apo B to Apo A1 was reduced more (p = 0.0866) in the amla group
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- 500 mg twice daily